Pharmacokinetics and anti-inflammatory pharmacodynamics of prednisolone in cynomolgus monkey PK-PD of prednisolone in monkeys

Xenobiotica

Volumn 39, Issue 11, 2009, Pages 862-870

  Zheng, Y J ^a   Hawk, M ^b   Yuan, H ^a   Hope, H R ^a   Baratta, M ^a   Zutshi, A ^a  

^a PFIZER INC   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Antiinflammatory; Cytokines; Monkey; Pharmacokinetic pharmacodynamic model; Prednisolone; Protein binding

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PREDNISOLONE SODIUM SUCCINATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; IC 50; MALE; MONKEY; NONHUMAN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; HALF-LIFE; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; PREDNISOLONE;

MACACA FASCICULARIS; PRIMATES;

EID: 70350315906     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903189454     Document Type: Article

References (34)

1. Almawi WY, Melemedjian OK. 2002. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 71:9-15.
2. Banker MJ, Clark TH, Williams JA. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974
3. Barth J, Damoiseaux M, Mollmann H, Brandis KH, Hochhaus G, Derendorf H. 1992. Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration. Int J Clin Pharmacol Ther Toxicol 30:317-324
4. Boudinot FD, Jusko WJ. 1986. Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. J Pharmacokinet Biopharm 14:453-467
5. Chakraborty A, Yeung S, Pyszczynski NA, Jusko WJ. 2005. Pharmacodynamic interactions between recombinant mouse interleukin-10 and prednisolone using a mouse endotoxemia model. J Pharm Sci 94:590-603.
6. Coe CL, Kramer M, Kirschbaum C, Netter P, Fuchs E. 2002. Prenatal stress diminishes the cytokine response of leukocytes to endotoxin stimulation in juvenile rhesus monkeys. J Clin Endocrinol Metab 87:675-681
7. Czock D, Keller F, Rasche FM, Haussler U. 2005. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61-98.
8. Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic response. J Pharmacokinet Biopharm 21:457-478
9. De Kruif MD, Lemaire LC, Giebelen IA, Van Zoelen MA, Pater JM, Van Den Pangaart PS, Groot AP, De Vos AF, Elliott PJ, Meijers JC, Levi M, Van der Poll T. 2007. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol 178:1845-1851
10. El Dareer SM, Struck RF, White VM, Mellett LB, Hill DL. 1977. Distribution and metabolism of prednisone in mice, dogs, and monkeys. Cancer Treat Rep 61:1279-1289
11. Feldmann M. 1996. The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target. J R Coll Physicians Lond 30:560-570
12. Frey BM, Frey FJ. 1990. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 19:126-146
13. Frey FJ, Frey BM, Greither A, Benet LZ. 1980. Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther 215:287-291
14. Frey FJ, Frey BM. 1982. Inequality of clearance values obtained by intravenous bolus and by steady-state infusion. Prednisolone studies in dogs. Pharmacology 24:346-354
15. Garrelds IM, Van Hal PT, Haakmat RC, Hoogsteden HC, Saxena PR, Zijlstra FJ. 1999. Time dependent production of cytokines and eicosanoids by human monocytic leukaemia U937 cells; effects of glucocorticosteroids. Mediators Inflamm 8:229-235
16. Hammarlund-Udenaes M, Benet LZ. 1991. Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. Biopharm Drug Dispos 12:467-477
17. Huang ML, Jusko WJ. 1990. Non-linear pharmacokinetics and interconversion of prednisolone and prednisone in rats. J Pharmacokinet Biopharm 18:401-421
18. Jusko WJ, Rose JQ. 1980. Monitoring prednisone and prednisolone. Ther Drug Monit 2:169-176
19. Kavanaugh A. 2002. Combination cytokine therapy: the next generation of rheumatoid arthritis therapy? Arthritis Rheum 47:87-92.
20. Kong AN, Jusko WJ. 1991. Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: non-linear and sequential first-pass elimination. J Pharm Sci 80:409-415
21. Lewis GP, Jusko WJ, Graves L, Burke CW. 1971. Prednisone sideeffects and serum-protein levels. A collaborative study. Lancet 2(7728):778-780
22. Meno-Tetang GM, Lowe PJ. 2005. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 96:182-192
23. Moreland LW, O'Dell JR. 2002. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 46:2553-2563
24. Petersen KB, Jusko WJ, Rasmussen M, Schmiegelow K. 2003. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 51:465-473 (Pubitemid 36791671)
25. Rocci ML Jr, D'Ambrosio R, Johnson NF, Jusko WJ. 1982. Prednisolone binding to albumin and transcortin in the presence of cortisol. Biochem Pharmacol 31:289-292
26. Rocci ML Jr, Johnson NF, Jusko WJ. 1980. Serum protein binding of prednisolone in four species. J Pharm Sci 69:977-978
27. Rohatagi S, Barth J, Mollmann H, Hochhaus G, Soldner A, Mollmann C, Derendorf H. 1997. Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration. J Clin Pharmacol 37:916-925
28. Rohatagi S, Hochhaus G, Mollmann H, Barth J, Derendorf H. 1995. Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Pharmazie 50:610-613
29. Rose JQ, Yurchak AM, Jusko WJ. 1981. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 9:389-417.
30. Rosman PM, Benn R, Kay M, Tito J, Wallace EZ. 1984a. Cortisol binding in uremic plasma. I. Absence of abnormal cortisol binding to cortisol binding to corticosteroid-binding globulin. Nephron 37:160-165
31. Rosman PM, Benn R, Kay M, Wallace EZ. 1984b. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin. Nephron 37:229-231
32. Wallwork B, Coman W, Feron F, Mackay-Sim A, Cervin A. 2002. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope 112:1827-1830
33. Ward KW, Coon DJ, Magiera D, Bhadresa S, Struharik M, Lawrence MS. 2009. Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions. Xenobiotica 39:266-272
34. Yamazaki M, Aoshima K, Mizutani T, Ontachi Y, Saito M, Morishita E, Asakura H, Matsuda T, Triplett DA. 1999. Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression. Blood Coagul Fibrinolysis 10:321-330